Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access
Orally bioavailable
Rapid-acting
Fewer dissociative effects
Depression and other indications
New Chemical Entity
Hallucinogenic and non-halluncingenic
Optimized duration of effect
Improved cardiac safety profile
Depression and other indications
New Chemical Entities
Rapid and sustained efficacy
Improved cardiac safety profile
Opioid abuse disorder and other indications
New Chemical Entity
We collaborate with research institutions at the forefront of biotech innovation.